IP Licensing Lawyers in 2026: A Market for Mid-Size Firms

IP licensing lawyers move to mid-size firms far more often than the rest of intellectual property does. Sartori & Partners data show that firms of 400-999 lawyers took 40.3% of lateral moves in IP transactions and licensing over the last 12 months, against 24.2% for intellectual property as a whole and 23.4% for the whole market. That puts them level with firms of 1,000+ lawyers, which took 38.7%. The work behind the moves is mostly life sciences: pharma and biotech clients appear on 71.1% of the licensing and transaction matters on record over 3 years. For a firm of 400-999 lawyers, this is a speciality where it already hires on equal terms with the largest firms. For a firm of 1,000+ lawyers, it is one where size wins fewer candidates than it does elsewhere in intellectual property.

Across intellectual property, firms of 1,000+ lawyers took 48.6% of lateral moves in 12 months and firms of 400-999 lawyers took 24.2%. In IP transactions and licensing the two classes sit side by side, at 38.7% and 40.3%. The mid-size share in licensing is 1.7 times the figure for intellectual property and 16.9 points above the market's. The longer window says the same. Over 3 years, firms of 400-999 lawyers took 34.3% of licensing moves, against 27.6% in intellectual property, so the 12-month figure is not one unusual year on a small base. The smaller classes stay close to the practice: firms of 150-399 lawyers took 12.9% of licensing moves and firms under 150 lawyers 8.1%, both rough sizes on small counts. The shift is between the two largest classes, and it runs toward the middle. For a firm of 400-999 lawyers the consequence is direct: in a licensing search it meets rivals of its own size for most candidates, and its platform does not start the conversation at a disadvantage.

In the Sartori & Partners records, 360 IP transactions and licensing matters reached the public record over 3 years, 140 of them in the last 12 months. Pharma and biotech clients appear on 71.1% of them. Media and entertainment follows at 14.7%, so life sciences clients show up 4.8 times as often. A matter can carry more than one industry or none, so the two shares are not a split of the whole. By type, M&A accounts for 13.1% of the matters, and most fall outside the standard deal types, at 55.0%. That fits the work itself: licenses, collaborations and technology transfers rarely look like a classic acquisition. These figures count matters, not fees, and they are no basis for ranking this speciality against another. What they do show is where the demand sits. A firm hiring for licensing is, in most cases, hiring for life sciences deal work, and the lawyer who brings it is one who has already run pharma and biotech licenses. A firm whose clients sit in other sectors is recruiting against the grain of the work.

Partners made 48.4% of IP transactions and licensing lateral moves in 12 months, against 34.4% in intellectual property and 27.7% across the market. Associates were 45.2% of licensing moves, against 49.7% in the practice. Sartori & Partners data show the tilt is not new: over 3 years the partner share in licensing was 44.3%, against 33.5% in intellectual property. Few of these moves come with a step up in title. Only 8.1% of licensing lawyers who moved joined at a higher title than the one they left, against 12.6% in intellectual property and 12.9% in the market. The home-grown route takes time. Firms promoted 27 lawyers in the speciality to partner in the 12 months from June 2025 to May 2026, and the median time to partner over 5 years was 10.0 years. A firm that needs a licensing partner should plan to hire one who already holds the title, at partner economics. Bringing in a counsel or senior associate to step up is a route this speciality uses less than the rest of intellectual property.

The volume is small and steady. In the Sartori & Partners lateral database, hiring in IP transactions and licensing held flat (+5.0%), with 63 lateral moves in the 12 months to September 2026 against 60 a year earlier. Intellectual property as a whole held flat (+7.2%), at 1,058 moves against 987. The whole market rose 9.0%, at 14,305 moves against 13,128. Partner hiring in the speciality also held flat, at 29 moves against 27. The speciality is a narrow slice of its practice: licensing moves recorded under intellectual property make up 5.7% of that practice's moves. In the latest 12 months, 62 licensing moves were spread over 50 hiring firms. A flat count in a pool this size means a firm competes for about the same number of movers as last year, while the market around it hires more lawyers in other practices. Supply will not ease by waiting, so a licensing search should start early and run with a long list.

The map is narrower than the practice's. Over 3 years, New York took 23.9% of IP transactions and licensing moves and Los Angeles 13.6%. Intellectual property as a whole placed 13.9% of its moves in New York and 6.2% in Los Angeles over the same window. The Los Angeles share in licensing is 2.2 times the practice's. Hiring is also more concentrated than in intellectual property.

The ten firms that hired most took 26.3% of the speciality's individual hires over 3 years, against 12.5% in intellectual property. Nixon Peabody ranks first, in the 6-10 band of lawyers hired. For a firm opening a licensing search, these are the names it is most likely to meet as rivals for the same candidates.

For a firm of 400-999 lawyers, IP licensing is a speciality where its size class wins as many lateral hires as firms of 1,000+ lawyers: 40.3% against 38.7%. It can bid for senior licensing talent without assuming the largest firms will take the pick of the market. For a firm of 1,000+ lawyers, its class share in licensing sits 9.9 points below its share across intellectual property, so it should expect a mid-size rival in the final round of most searches. For every hiring firm, the brief is a partner who already holds the title, has run pharma and biotech licenses, and sits in New York or Los Angeles. The pool is flat and small, few movers step up in title, and the firms hiring most recur. Start early, budget for partner economics, and judge candidates on the life sciences clients they act for today.